Caribou Biosciences to Present at 40th Annual J.P. Morgan Healthcare Conference
January 04 2022 - 4:05PM
Caribou Biosciences, Inc. (Nasdaq:CRBU), a leading clinical-stage
CRISPR genome-editing biopharmaceutical company, announced today
that Rachel Haurwitz, Ph.D., Caribou’s president and chief
executive officer, will present a corporate update at the 40th
Annual J.P. Morgan Healthcare Conference on Thursday, January 13,
2022 at 9:45 am ET.
A live webcast of the presentation will be accessible via
Caribou’s website on the Events page. The archived webcast will be
available on the Caribou website for 30 days after the event.
About Caribou’s Novel Next-Generation CRISPR
PlatformCRISPR genome editing uses easily designed,
modular biological tools to make DNA changes in living cells. There
are two basic components of Type II CRISPR systems: the nuclease
protein that cuts DNA and the RNA molecule(s) that guide the
nuclease to generate a site-specific, double-stranded break,
leading to an edit at the targeted genomic site. CRISPR systems
occasionally edit unintended genomic sites, known as off-target
editing, which may lead to harmful effects on cellular function and
phenotype. In response to this challenge, Caribou has developed
chRDNAs (pronounced “chardonnays”), RNA-DNA hybrid guides that
direct substantially more precise genome editing compared to
all-RNA guides. Caribou is deploying the power of its Cas12a chRDNA
technology to carry out high efficiency multiple edits, including
multiplex gene insertions, to develop CRISPR-edited therapies.
About Caribou Biosciences, Inc. Caribou is a
clinical-stage CRISPR genome-editing biopharmaceutical company
dedicated to transforming the lives of patients with devastating
diseases by applying the company’s proprietary Cas12a chRDNA
technology toward the development of next-generation, genome-edited
cell therapies. The company is developing a pipeline of
genome-edited, off-the-shelf CAR-T and CAR-NK cell therapies for
the treatment of both hematologic malignancies and solid tumors
against cell surface targets for which autologous CAR-T cell
therapeutics have previously demonstrated clinical proof of
concept, as well as additional emerging targets.
For more information about Caribou, visit www.cariboubio.com and
follow the company @CaribouBio.
“Caribou Biosciences” and the Caribou logo are registered
trademarks of Caribou Biosciences, Inc.
Caribou Biosciences, Inc.
Contact:Amy Figueroa, CFAInvestor Relations and
Corporate
Communicationsafigueroa@cariboubio.comInvestors:Elizabeth
Wolffe, Ph.D., and Sylvia WheelerWheelhouse
LSAlwolffe@wheelhouselsa.com swheeler@wheelhouselsa.comMedia:Greg
KelleyOgilvygregory.kelley@ogilvy.com617-461-4023
Caribou Biosciences (NASDAQ:CRBU)
Historical Stock Chart
From Jun 2024 to Jul 2024
Caribou Biosciences (NASDAQ:CRBU)
Historical Stock Chart
From Jul 2023 to Jul 2024